Hudson Bay Capital Management LP Biogen Inc. Transaction History

Hudson Bay Capital Management LP

$28.9 Billion
Q1 2025

A detailed history of Hudson Bay Capital Management LP transactions in Biogen Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 200,520 shares of BIIB stock, worth $26 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

200,520

Previous 241,008 16.8%

Holding current value

$26 Million

Previous $36.9 Million 25.55%

% of portfolio

0.09%

Previous 0.15%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$133.43 - $153.27 $5.4 Million - $6.21 Million	-40,488 Reduced 16.8%	200,520 $27.4 Million
Q4 2024 Feb 14, 2025	SELL	$146.47 - $191.55 $8.64 Million - $11.3 Million	-58,992 Reduced 19.66%	241,008 $36.9 Million
Q3 2024 Nov 13, 2024	BUY	$189.07 - $236.8 $19.9 Million - $24.9 Million	105,000 Added 53.85%	300,000 $58.2 Million
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $5.72 Million - $7.1 Million	-30,000 Reduced 13.33%	195,000 $45.2 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $19.1 Million - $24.1 Million	90,000 Added 66.67%	225,000 $48.5 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $11.7 Million - $14.1 Million	52,500 Added 63.64%	135,000 $34.9 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $6.33 Million - $7.15 Million	25,000 Added 43.48%	82,500 $21.2 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $14.3 Million - $16.5 Million	-51,806 Reduced 47.4%	57,500 $16.4 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $14.6 Million - $16.6 Million	56,806 Added 108.2%	109,306 $30.4 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $1.26 Million - $1.53 Million	5,000 Added 10.53%	52,500 $14.5 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $4.38 Million - $6.04 Million	22,500 Added 90.0%	47,500 $12.7 Million
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $1.88 Million - $2.23 Million	10,000 Added 66.67%	25,000 $5.1 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $5.62 Million - $7.08 Million	-29,000 Reduced 65.91%	15,000 $3.16 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $5.37 Million - $6.91 Million	24,000 Added 120.0%	44,000 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $1.41 Million - $1.85 Million	5,000 Added 33.33%	20,000 $5.66 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $3.89 Million - $6.22 Million	15,000 New	15,000 $5.19 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $4.86 Million - $5.69 Million	-20,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $7.09 Million - $10.7 Million	-30,000 Reduced 60.0%	20,000 $4.9 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $661,925 - $764,275	2,500 Added 5.26%	50,000 $14.2 Million
Q2 2020 Aug 12, 2020	BUY	$258.66 - $342.55 $9.7 Million - $12.8 Million	37,500 Added 375.0%	47,500 $12.7 Million
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $2.69 Million - $3.41 Million	10,000 New	10,000 $3.16 Million
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $1.63 Million - $1.83 Million	-7,500 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $5.77 Million - $6.36 Million	-26,300 Reduced 77.81%	7,500 $1.75 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $4.14 Million - $6.47 Million	19,100 Added 129.93%	33,800 $7.99 Million
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $4.26 Million - $5.4 Million	-15,300 Reduced 51.0%	14,700 $4.42 Million
Q2 2018 Aug 13, 2018	SELL	$257.52 - $306.91 $2.58 Million - $3.07 Million	-10,000 Reduced 25.0%	30,000 $8.71 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $6.5 Million - $9.2 Million	25,000 Added 166.67%	40,000 $11 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $4.22 Million - $4.95 Million	15,000	15,000 $4.7 Million

Others Institutions Holding BIIB

# of Institutions

1,026

Shares Held

127M

Call Options Held

2.29M

Put Options Held

4.26M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $18.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Biogen Inc. Transaction History